
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

72081
10.1038/s41598-024-72081-z
Article
Elevated body mass index is not significantly associated with reduced influenza vaccine effectiveness
King Jennifer P. King.jennifer@marshfieldresearch.org

1
Nguyen Huong Q. 1
Kiniry Erika L. 2
Phillips C. Hallie 2
Gaglani Manjusha 34
Martin Emily T. 5
Geffel Krissy Moehling 6
Nowalk Mary Patricia 6
Chung Jessie R. 7
Flannery Brendan 7
Belongia Edward A. 1
1 https://ror.org/025chrz76 grid.280718.4 0000 0000 9274 7048 Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Institute (ML2), 1000 N. Oak Ave, Marshfield, WI 54449 USA
2 https://ror.org/0027frf26 grid.488833.c 0000 0004 0615 7519 Kaiser Permanente Washington Health Research Institute, Seattle, WA USA
3 grid.486749.0 0000 0004 4685 2620 Baylor College of Medicine, Baylor Scott & White Health, Dallas, TX USA
4 https://ror.org/01f5ytq51 grid.264756.4 0000 0004 4687 2082 Texas A&M University College of Medicine, Temple, TX USA
5 https://ror.org/00jmfr291 grid.214458.e 0000 0004 1936 7347 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI USA
6 https://ror.org/01an3r305 grid.21925.3d 0000 0004 1936 9000 Department of Family Medicine, University of Pittsburgh, Pittsburgh, PA USA
7 https://ror.org/042twtr12 grid.416738.f 0000 0001 2163 0069 Influenza Division, US Centers for Disease Control and Prevention, Atlanta, GA USA
13 9 2024
13 9 2024
2024
14 214669 6 2024
3 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Elevated body mass index (BMI) has been linked to severe influenza illness and impaired vaccine immunogenicity, but the relationship between BMI and clinical vaccine effectiveness (VE) is less well described. This secondary analysis of data from a test-negative study of outpatients with acute respiratory illness assessed BMI and VE against medically attended, PCR-confirmed influenza over seven seasons (2011–12 through 2017–18). Vaccination status was determined from electronic medical records (EMR) and self-report; BMI was estimated from EMR-documented height and weight categorized for adults as obesity (≥ 30 kg/m2), overweight (25–29 kg/m2), or normal and for children based on standardized z-scales. Current season VE by virus type/subtype was estimated separately for adults and children. Pooled VE for all seasons was calculated as 1—adjusted odds ratios from logistic regression with an interaction term for BMI and vaccination. Among 28,089 adults and 12,380 children, BMI category was not significantly associated with VE against outpatient influenza for any type/subtype. Adjusted VE against A/H3N2, A/H1N1pdm09, and B in adults ranged from 16–31, 46–54, and 44–57%, and in children from 29–34, 57–65, and 50–55%, respectively, across the BMI categories. Elevated BMI was not associated with reduced VE against laboratory confirmed, outpatient influenza illness.

Keywords

Vaccine effectiveness
Body mass index
Influenza
Obesity
Subject terms

Influenza virus
Preventive medicine
Body mass index
http://dx.doi.org/10.13039/100000030 Centers for Disease Control and Prevention 1U01IP001038 http://dx.doi.org/10.13039/100000002 National Institutes of Health 1UL1 TR001857 issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

According to the World Health Organization, about 16% of adults aged 18 years and older worldwide had obesity in 2022. The worldwide prevalence of obesity more than doubled between 1990 and 20221. In the United States, obesity affects over 40% of adults and nearly 20% of children2,3. Obesity is associated with metabolic syndrome and other comorbid conditions, and it may contribute to more severe influenza illness in children and adults4–11.

The effects of obesity on the immune response to influenza vaccination are complex and poorly understood. Post-vaccination hemagglutinin inhibition (HI) titers to influenza antigens are largely similar in individuals with obesity and normal weight12–14. However, antibody titers appear to decline more rapidly in people with higher body mass index (BMI), and aspects of the cell-mediated immune response may be inhibited13,15–17.

The relationship between BMI and clinical vaccine effectiveness (VE) is even less clear as few studies have addressed this question. A prospective observational study reported similar protection against PCR-confirmed influenza illness in vaccinated children with and without obesity18. While there are no published VE estimates comparing adults with and without obesity, a two-season prospective study in vaccinated adults found that influenza or influenza-like illness (ILI) was associated with obesity despite similar levels of seroprotective antibodies19. However, the study was limited by a small sample size, nonspecific endpoint (ILI), likely residual confounding, and lack of an unvaccinated comparison group.

To further elucidate the relationship between obesity and influenza VE in the outpatient setting, we analyzed data from the US influenza (Flu) VE network over seven seasons.

Methods

This analysis included data from the Flu VE Network from 2011–12 through 2017–1820. Details of the study population and procedures have been previously described21,22. In brief, patients seeking medical care for an acute respiratory illness (ARI) with cough and illness of ≤ 7 days duration were recruited from outpatient, urgent care, and emergency department facilities in Michigan, Pennsylvania, Texas, Washington, and Wisconsin. The institutional review boards (IRB) at the Centers for Disease Control and Prevention (CDC) and all participating sites (Marshfield Clinic Health System IRB, Group Health Cooperative Human Subjects Review Committee/Kaiser Permanente-Washington Region IRB, Baylor Scott & White Research Institute IRB, University of Michigan IRBMED, and University of Pittsburgh Human Research Protection Office) approved the study. The study was performed in accordance with Health and Human Services regulations for the protection of human subjects in research (specifically 45 CFR 46, 21 CFR 50, and 21 CFR 56). Participants/legal guardians provided informed consent prior to participating. Consenting participants/legal guardians completed an enrollment interview to ascertain demographics, symptoms, onset date, current season vaccination, and subjective assessments of general and current health status. Anterior or mid-turbinate nasal and throat swabs were collected from participants by research staff and tested for influenza type and subtype by real-time reverse transcription polymerase chain reaction (rRT-PCR) at network sites. Presence of underlying medical conditions was defined as one or more International Classification of Diseases, Ninth/Tenth Revision (ICD-9/10) codes diagnosed for medical encounters in the previous year.

Influenza vaccination status

Participants with electronic medical record (EMR) documented vaccine receipt of ≥ 1 dose of current season influenza vaccine or undocumented but plausible self- or parent-reported vaccination 14 or more days before symptom onset were classified as vaccinated. Plausible self-report was determined by sites as receipt of vaccination during times influenza vaccination is typically offered and from providers (e.g. Veterans Affairs, Indian Health Service) not routinely reported to immunization information systems. Participants vaccinated < 14 days before onset were excluded from analysis.

Body mass index (BMI)

Height and weight measurements closest in time to enrollment were extracted from EMR. BMI in adults was grouped into categories according to National Heart, Lung and Blood Institute (NHLBI) definitions: < 18.5 kg/m2 (underweight), 18.5 to < 25 kg/m2 (normal, reference category), 25 to < 30 kg/m2 (overweight), and ≥ 30 kg/m2 (obesity)23,24. For children and adolescents, the publicly available SAS Program for the 2000 CDC Growth Charts was used to calculate BMI category for children 24 months (2 years) to 17 years of age based on percentile ranges for BMI by age and sex, with < 5th percentile, underweight, 5 to < 85th percentile, normal (reference category), 85 to < 95th percentile, overweight and ≥ 95th percentile, obesity25,26.

Height and weight data were only included if within plausible ranges. For adults ≥ 18 years of age, height ≥ 44 inches and ≤ 90 inches, weight ≥ 55 pounds and ≤ 1000 pounds, and BMI ≥ 12 and ≤ 70 were considered plausible27. For children, plausible values for height, weight, and BMI were defined by z scores calculated from the percentile of weight-, height- and BMI-for-age (in months) scores of the child25. We excluded pregnant women, underweight individuals, adults with weight measurements obtained more than 12 months from enrollment date, and children with height or weight measurements more than 6 months from enrollment date. Analyses were restricted to children aged ≥ 24 months.

Analytic approach

Influenza cases were persons with rRT-PCR positive tests for influenza A/H3N2, A/H1N1pdm09, or B viruses. Participants with unsubtypable influenza A or inconclusive results or with co-infections with multiple influenza viruses were excluded. Controls were persons testing rRT-PCR negative for all influenza subtypes/types. The analysis period was defined at each site, for each season, and for each type/subtype. The period was determined as the calendar week of enrollment from the first rRT-PCR positive influenza case of the specific type/subtype at that site through the last confirmed case of that type/subtype at that site. Seasons with 50 or more virus type/subtype specific cases were pooled; sites with 10 or more virus type/subtype specific cases were included in pooled analyses for the respective seasons and type/subtype.

We generated multivariable logistic regression models with influenza case status as the outcome. VE was estimated as (1-aOR) × 100, where aOR is the adjusted odds ratio for influenza among vaccinated compared with unvaccinated persons28,29. Vaccination status, age, network site, and enrollment season, were included in all adjusted models a priori. Age was modeled as a linear tail-restricted natural cubic spline for adults and as categories (2–8 years and 9–17 years) for children and adolescents. The pediatric age cut off was selected for consistency with influenza vaccine recommendations30. Records with missing data for influenza result, BMI, or model covariates were not included in the final analyses. Additional covariates were evaluated and retained in the model if the coefficient for the vaccination status differed by ≥ 10%. Covariates examined included: calendar time relative to the season peak at each site and type/subtype; time from illness onset to enrollment; presence of ≥ 1 underlying medical condition other than obesity; sex; self-reported health status; race/ethnicity; and smoking status (in adults only). We evaluated modification of VE by participant BMI by including an interaction term in models. Evidence of interaction was defined a priori at p < 0.10. Separate models were generated for children and adults, and A/H3N2, A/H1N1pdm09, and type B associated illness.

We used models restricted to vaccinated participants, with odds of influenza as the outcome and BMI as the exposure, to assess differential odds of breakthrough illness among vaccinated participants with obesity versus those with normal BMI as the reference group. Time from vaccination to illness onset (< 90 days vs ≥ 90 days) was included as a covariate in addition to the other a priori covariates to account for waning vaccine effects.

Sensitivity analyses

For A/H3N2, the 2014–15 season was excluded in sensitivity analyses because circulating A/H3N2 viruses were not antigenically matched to the vaccine virus. Among adults, a BMI of ≥ 40 (class 3 obesity) is currently used to define individuals at increased risk for severe outcomes from influenza so we performed an additional sensitivity analysis creating a four level BMI term by dividing the obesity category into obesity (30 to < 40) and class 3 obesity (BMI ≥ 40). To assess potential differences among older adults, sensitivity analyses were restricted to adults ≥ 65 years of age.

Results

From 2011–12 through 2017–18, 31 647 adults were enrolled in the Flu VE Network, of whom 28 089 were included in this analysis (Supplemental Fig. 1). Among eligible adults, 6 259 (22%) had a normal weight BMI, 8 338 (30%) had an overweight BMI, and 13 492 (48%) had an obese BMI (Table 1). Among those with obese BMI, 25% (12% of adults overall) would be considered class 3 obesity with a BMI ≥ 40. Most participants were non-Hispanic White (80%), 26% had an underlying medical condition other than obesity, and 54% were vaccinated with 37% of those receiving vaccine less than 90 days prior to illness onset. 9% of vaccination dates were determined from self-report (data not shown). Compared to individuals of normal weight, a greater percentage of participants with obesity were non-Hispanic Black, or Hispanic, had an underlying medical condition, and had received the current season influenza vaccine. A higher percentage of adult participants with BMI in normal ranges reported excellent/very good general health compared to individuals with BMI in the obesity range. Table 1 Characteristics of adults categorized by body mass index, 2011–12 through 2017–18.

		BMI category*	
	Total (n = 28089)	Normal weight (n = 6259, 22%)	Overweight (n = 8338, 30%)	Obesity (n = 13492, 48%)	
Age, mean (SD)	48.2 (17.6)	43.8 (19.5)	50.1 (18.2)	49.1 (16.0)	
Site	
 Michigan	3941 (14)	808 (13)	1159 (14)	1974 (15)	
 Pennsylvania	5511 (20)	1442 (23)	1675 (20)	2394 (18)	
 Texas	5155 (18)	954 (15)	1459 (18)	2742 (20)	
 Washington	7829 (28)	2040 (33)	2487 (30)	3302 (24)	
 Wisconsin	5653 (20)	1015 (16)	1558 (19)	3080 (23)	
Male	10365 (37)	1840 (29)	3649 (44)	4876 (36)	
Race	
 Non-hispanic white	22490 (80)	5063 (81)	6755 (81)	10672 (79)	
 Non-hispanic black	1754 (6)	227 (4)	431 (5)	1096 (8)	
 Non-hispanic, other race	2050 (7)	638 (10)	629 (8)	783 (6)	
 Hispanic, any race	1716 (6)	308 (5)	496 (6)	912 (7)	
 Missing	23 (0)	27 (0)	29 (0)	79 (0)	
Underlying medical condition other than obesity	7245 (26)	1069 (17)	1981 (24)	4195 (31)	
Self-reported general health status	
 Excellent/very good	17147 (61)	4546 (73)	5632 (68)	6969 (52)	
 Good	8310 (30)	1308 (21)	2145 (26)	4857 (36)	
 Fair/poor	2601 (9)	395 (6)	553 (7)	1653 (12)	
 Refused	31 (0)	10 (0)	8 (0)	13 (0)	
Vaccinated	15285 (54)	3170 (51)	4640 (56)	7475 (55)	
  < 90 days before onset	5596 (37)	1167 (37)	1749 (38)	2680 (36)	
Influenza test result	
 Negative	20747 (74)	4555 (73)	6044 (72)	10148 (75)	
 A/H3N2	4008 (14)	925 (15)	1247 (15)	1836 (14)	
 A/H1N1pdm09	1461 (5)	363 (6)	454 (5)	644 (5)	
 B	1873 (7)	416 (7)	593 (7)	864 (6)	
Onset to enrollment interval	
 0–2 days	8170 (29)	1823 (29)	2340 (28)	4007 (30)	
 3–4 days	11103 (40)	2431 (39)	3338 (40)	5334 (40)	
 5–7 days	8816 (31)	2005 (32)	2660 (32)	4151 (31)	
Season	
 2011–12	1958 (7)	429 (7)	575 (7)	954 (7)	
 2012–13	3356 (12)	754 (12)	1053 (13)	1549 (11)	
 2013–14	3616 (13)	814 (13)	1123 (13)	1679 (12)	
 2014–15	5296 (19)	1181 (19)	1575 (19)	2540 (19)	
 2015–16	4075 (15)	994 (16)	1160 (14)	1921 (14)	
 2016–17	4449 (16)	920 (15)	1334 (16)	2195 (16)	
 2017–18	5339 (19)	1167 (19)	1518 (18)	2654 (20)	
Data presented as number (n), column percent (%) unless otherwise noted.

BMI body mass index, SD standard deviation.

*BMI categories: Normal (18.5 to < 25 kg/m2), Overweight (25 to < 30 kg/m2), Obesity (≥ 30 kg/m2).

Compared to non-influenza controls, among adult participants lower percentages of influenza case participants had BMI in the obese range, were male, less likely to rank their general health as poor to fair and to have received current season influenza vaccine (Table 2). Across all types/subtypes, controls were more likely to be enrolled later in illness (5–7 days from onset) compared to cases. Table 2 Characteristics of cases and controls by influenza type in adults, 2011–12 through 2017–18*.

	A/H3N2		A/H1N1pdm09		B		
	Controls (n = 13800)	Cases (n = 3919)	Controls (n = 9143)	Cases (n = 1361)	Controls (n = 14632)	Cases (n = 1804)	
BMI†	
 Normal weight	2963 (21)	903 (23)	2052 (22)	341 (25)	3201 (22)	399 (22)	
 Overweight	4025 (29)	1217 (31)	2623 (29)	417 (31)	4246 (29)	569 (32)	
 Obesity	6812 (49)	1799 (46)	4468 (49)	603 (44)	7185 (49)	836 (46)	
Age, mean (SD)	48.4 (17.6)	50.2 (18.2)	47.9 (17.9)	45.8 (15.2)	47.9 (17.8)	50.0 (16.0)	
Site	
 Michigan	2310 (17)	661 (17)	995 (11)	164 (12)	1660 (11)	199 (11)	
 Pennsylvania	2244 (16)	852 (22)	1958 (21)	433 (32)	2584 (18)	331 (18)	
 Texas	2434 (18)	600 (15)	1644 (18)	156 (11)	3231 (22)	354 (20)	
 Washington	3961 (29)	848 (22)	2844 (31)	246 (18)	4404 (30)	451 (25)	
 Wisconsin	2851 (21)	958 (24)	1702 (19)	362 (27)	2753 (19)	469 (26)	
Male	4999 (36)	1531 (39)	3128 (34)	580 (43)	5124 (35)	763 (42)	
Race	
 Non-hispanic white	11008 (80)	3175 (81)	7296 (80)	1099 (81)	11694 (80)	1472 (81)	
 Non-hispanic black	853 (6)	234 (6)	546 (6)	99 (7)	813 (6)	103 (6)	
 Non-hispanic, other race	1068 (8)	270 (7)	707 (8)	89 (7)	1133 (8)	117 (7)	
 Hispanic, any race	842 (6)	223 (6)	566 (6)	70 (5)	961 (7)	107 (6)	
 Missing	29 (0)	17 (0)	28 (0)	4 (0)	31 (0)	5 (0)	
Underlying medical condition other than obesity	3827 (28)	1104 (28)	2515 (28)	217 (16)	4102 (28)	474 (26)	
Self-reported general health status	
 Excellent/very good	8232 (60)	2483 (63)	5529 (60)	914 (67)	8814 (60)	1198 (66)	
 Good	4212 (31)	1122 (29)	2774 (30)	340 (25)	4444 (30)	466 (26)	
 Fair/poor	1344 (10)	305 (8)	833 (9)	106 (8)	1362 (9)	139 (8)	
 Refused	12 (0)	9 (0)	7 (0)	1 (0)	12 (0)	1 (0)	
Vaccinated	7968 (58)	2093 (53)	5148 (56)	498 (37)	8358 (57)	761 (42)	
  < 90 days before onset	2961 (37)	895 (43)	1871 (36)	176 (35)	2816 (34)	175 (23)	
Calendar time‡	
 Pre-peak	3384 (25)	760 (19)	2602 (28)	275 (20)	6196 (42)	324 (18)	
 Peak	4636 (34)	2345 (60)	3379 (37)	827 (61)	6188 (42)	1112 (62)	
 Post-peak	5780 (42)	814 (21)	3162 (34)	259 (19)	2248 (15)	368 (20)	
Onset to enrollment interval	
 0–2 days	3512 (25)	1746 (45)	2324 (25)	633 (47)	3759 (26)	525 (29)	
 3–4 days	5510 (40)	1506 (38)	3533 (39)	496 (36)	5747 (39)	803 (45)	
 5–7 days	4778 (35)	667 (17)	3286 (36)	232 (17)	5126 (35)	476 (26)	
Season	
 2011–12	1281 (9)	176 (4)	0 (0)	0 (0)	892 (6)	51 (3)	
 2012–13	2237 (16)	738 (19)	0 (0)	0 (0)	1551 (11)	341 (19)	
 2013–14	0 (0)	0 (0)	2667 (29)	734 (54)	0 (0)	0 (0)	
 2014–15	3782 (27)	1071 (27)	0 (0)	0 (0)	3762 (26)	226 (13)	
 2015–16	0 (0)	0 (0)	3147 (34)	468 (34)	2092 (14)	218 (12)	
 2016–17	3172 (23)	868 (22)	0 (0)	0 (0)	2961 (20)	360 (20)	
 2017–18	3328 (24)	1066 (27)	3329 (36)	159 (12)	3374 (23)	608 (34)	
Data presented as number (n), column percent (%) unless otherwise noted.

BMI body mass index, SD standard deviation.

*Cases and controls included in this table are from seasons with 50 or more cases of the specific virus and sites that had 10 or more cases of the specific virus.

†BMI categories: Normal (18.5 to < 25 kg/m2), Overweight (25 to < 30 kg/m2), Obesity (≥ 30 kg/m2).

‡Peak defined as the weeks during which the middle 50% of all cases of the type/subtype occurred during the season at each site.

From 2011–12 through 2017–18, 16 636 children were enrolled in the Flu VE Network, of whom 12 380 were included in this analysis (Supplemental Fig. 1). Among eligible children 7 860 (63%) had a normal range BMI, 2 018 (16%) had an overweight range BMI, and 2 502 (20%) had an obese range BMI. Most were non-hispanic white (64%), 4% had an underlying medical condition other than obesity in the previous year, 45% were vaccinated, 18% of vaccinated children received live attenuated influenza vaccine (LAIV) and 41% of vaccinated children received vaccine less than 90 days prior to illness onset (Table 3). Less than 1% of vaccination dates were determined from self-report (data not shown). Children with obese range BMI were more frequently enrolled from the Texas site, non-Hispanic Black or Hispanic, female, and 9–17 years of age compared with children of normal weight and overweight range. Children with obesity were more likely to have an underlying medical condition and less likely to report excellent or very good health status or be vaccinated compared to children with normal weight and children with overweight BMI. There were multiple demographic and clinical differences between pediatric influenza cases and controls (Table 4). Across all influenza types, controls were more likely to be vaccinated. Table 3 Characteristics of children and adolescents categorized by body mass index, 2011–12 through 2017–18.

		BMI Category*	
	Total (n = 12380)	Normal weight (n = 7860, 63%)	Overweight (n = 2018, 16%)	Obesity (n = 2502, 20%)	
Age category	
 2–8 Years	7182 (58)	4837 (62)	1139 (56)	1206 (48)	
 9–17 years	5198 (42)	3023 (38)	879 (44)	1296 (52)	
Site	
 Michigan	2448 (20)	1596 (20)	398 (20)	454 (18)	
 Pennsylvania	1539 (12)	957 (12)	267 (13)	315 (13)	
 Texas	3199 (26)	1861 (24)	501 (25)	837 (33)	
 Washington	1886 (15)	1289 (16)	317 (16)	280 (11)	
 Wisconsin	3308 (27)	2157 (27)	535 (27)	616 (25)	
Male	6335 (51)	3965 (50)	1009 (50)	1361 (54)	
Race	
 Non-hispanic white	7938 (64)	5252 (67)	1303 (65)	1383 (55)	
 Non-hispanic black	1232 (10)	706 (9)	197 (10)	329 (13)	
 Non-hispanic, other race	1344 (11)	860 (11)	220 (11)	264 (11)	
 Hispanic, any race	1844 (15)	1027 (13)	295 (15)	522 (21)	
 Missing	22 (0)	15 (0)	3 (0)	4 (0)	
Underlying medical condition other than obesity	493 (4)	282 (4)	73 (4)	138 (6)	
Self-reported general health status	
 Excellent/very good	10272 (83)	6674 (85)	1693 (84)	1905 (76)	
 Good	1741 (14)	989 (13)	266 (13)	486 (19)	
 Fair/poor	356 (3)	189 (2)	56 (3)	111 (4)	
 Refused	11 (0)	8 (0)	3 (0)	0 (0)	
Vaccinated	5517 (45)	3557 (45)	917 (45)	1043 (42)	
  < 90 days before onset	2252 (41)	1441 (41)	383 (42)	428 (41)	
  Received LAIV	973 (18)	676 (19)	159 (17)	138 (13)	
Influenza test result	
 Negative	9055 (73)	5647 (72)	1502 (74)	1906 (76)	
 A/H3N2	1842 (15)	1247 (16)	281 (14)	314 (13)	
 A/H1N1pdm09	388 (3)	266 (3)	58 (3)	64 (3)	
 B	1095 (9)	700 (9)	177 (9)	218 (9)	
Onset to enrollment interval	
 0–2 days	5087 (41)	3180 (40)	862 (43)	1045 (42)	
 3–4 days	4670 (38)	2990 (38)	724 (36)	956 (38)	
 5–7 days	2623 (21)	1690 (22)	432 (21)	501 (20)	
Season	
 2011–12	1303 (11)	827 (11)	226 (11)	250 (10)	
 2012–13	1802 (15)	1116 (14)	272 (13)	414 (17)	
 2013–14	1246 (10)	809 (10)	199 (10)	238 (10)	
 2014–15	2680 (22)	1715 (22)	446 (22)	519 (21)	
 2015–16	1410 (11)	890 (11)	217 (11)	303 (12)	
 2016–17	1832 (15)	1153 (15)	315 (16)	364 (15)	
 2017–18	2107 (17)	1350 (17)	343 (17)	414 (17)	
BMI body mass index, LAIV live attenuated influenza vaccine.

*BMI categories: Normal (BMI percent 5 to < 85), Overweight (BMI percent 85 to < 95), Obesity (BMI percent ≥ 95).

Table 4 Characteristics of cases and controls by influenza type in children and adolescents, 2011–12 through 2017–18*.

	A/H3N2		A/H1N1pdm09		B		
	Controls (n = 6257)	Cases (n = 1809)	Controls (n = 2936)	Cases (n = 325)	Controls (n = 5636)	Cases (n = 1034)	
BMI†	
 Normal	3890 (62)	1223 (68)	1825 (62)	228 (70)	3448 (61)	660 (64)	
 Overweight	1060 (17)	278 (15)	474 (16)	45 (14)	949 (17)	168 (16)	
 Obesity	1307 (21)	308 (17)	637 (22)	52 (16)	1239 (22)	206 (20)	
Age category	
 2–8 years	3814 (61)	887 (49)	1738 (59)	226 (70)	3337 (59)	494 (48)	
 9–17 years	2443 (39)	922 (51)	1198 (41)	99 (30)	2299 (41)	540 (52)	
Site	
 Michigan	1478 (24)	473 (26)	413 (14)	52 (16)	757 (13)	218 (21)	
 Pennsylvania	708 (11)	216 (12)	514 (18)	87 (27)	650 (12)	65 (6)	
 Texas	1516 (24)	390 (22)	926 (32)	67 (21)	1931 (34)	289 (28)	
 Washington	882 (14)	167 (9)	175 (6)	19 (6)	941 (17)	113 (11)	
 Wisconsin	1673 (27)	563 (31)	908 (31)	100 (31)	1357 (24)	349 (34)	
Male	3189 (51)	918 (51)	1477 (50)	163 (50)	2888 (51)	551 (53)	
Race	
 Non-hispanic white	4001 (64)	1183 (66)	1920 (66)	208 (64)	3526 (63)	656 (64)	
 Non-hispanic black	622 (10)	208 (12)	273 (9)	47 (15)	509 (9)	101 (10)	
 Non-hispanic, other race	694 (11)	176 (10)	278 (9)	31 (10)	589 (11)	115 (11)	
 Hispanic, any race	928 (15)	239 (13)	458 (16)	38 (12)	1000 (18)	159 (15)	
 Missing	12 (0)	3 (0)	7 (0)	1 (0)	12 (0)	3 (0)	
Underlying medical condition other than obesity	282 (5)	60 (3)	125 (4)	12 (4)	267 (5)	37 (4)	
Self-reported health	
 Excellent/very good	5117 (82)	1552 (86)	2440 (83)	277 (85)	4605 (82)	874 (85)	
 Good	937 (15)	211 (12)	419 (14)	38 (12)	853 (15)	134 (13)	
 Fair/poor	201 (3)	41 (2)	75 (3)	10 (3)	175 (3)	26 (3)	
 Refused	2 (0)	5 (0)	2 (0)	0 (0)	3 (0)	0 (0)	
Vaccinated	3062 (49)	688 (38)	1372 (47)	90 (28)	2700 (48)	300 (29)	
  < 90 days before onset	1314 (43)	339 (49)	552 (40)	33 (37)	1107 (41)	96 (32)	
  Received LAIV	504 (16)	117 (17)	163 (12)	33 (37)	445 (16)	44 (15)	
Calendar time‡	
 Pre-peak	1632 (26)	306 (17)	748 (25)	61 (19)	2473 (44)	247 (24)	
 Peak	1982 (32)	1141 (63)	1023 (35)	201 (62)	2300 (41)	628 (61)	
 Post-peak	2643 (42)	362 (20)	1165 (40)	63 (19)	863 (15)	159 (15)	
Onset to enrollment interval	
 0–2 days	2485 (40)	934 (52)	1193 (41)	150 (46)	2240 (40)	475 (46)	
 3–4 days	2384 (38)	605 (33)	1096 (37)	108 (33)	2143 (38)	395 (38)	
 5–7 days	1388 (22)	270 (15)	647 (22)	67 (21)	1253 (22)	164 (16)	
Season	
 2011–12	698 (11)	130 (7)	0 (0)	0 (0)	0 (0)	0 (0)	
 2012–13	1075 (17)	324 (18)	0 (0)	0 (0)	881 (16)	390 (38)	
 2013–14	0 (0)	0 (0)	997 (34)	164 (50)	0 (0)	0 (0)	
 2014–15	1962 (31)	525 (29)	0 (0)	0 (0)	1625 (29)	111 (11)	
 2015–16	0 (0)	0 (0)	892 (30)	82 (25)	746 (13)	119 (12)	
 2016–17	1285 (21)	345 (19)	0 (0)	0 (0)	1250 (22)	181 (18)	
 2017–18	1237 (20)	485 (27)	1047 (36)	79 (24)	1134 (20)	233 (23)	
BMI body mass index, LAIV live attenuated influenza vaccine.

*Cases and controls included in this table are from seasons with 50 or more cases of the specific virus and sites that had 10 or more cases of the specific virus.

†BMI categories: Normal (BMI percent 5 to < 85), Overweight (BMI percent 85 to < 95), Obesity (BMI percent ≥ 95).

‡Peak defined as the weeks during which the middle 50% of all cases of the type/subtype occurred during the season at each site.

By influenza virus type/subtype and BMI category, VE estimates in adults against A/H3N2 varied from 16% (95% confidence interval (CI) 2, 28%) to 31% (95% CI 21, 39%), against A/H1N1pdm09 from 46% (95% CI 30, 58%) to 54% (95% CI 42, 63%), and against type B from 44% (95% CI 31, 55%) to 57% (48, 64%) (Fig. 1). Results were similar in a sensitivity analysis that excluded adults with vaccination based on self-report. In children and adolescents, VE estimates by influenza virus type/subtype and BMI category varied from 29% (95% CI 7, 45%) to 34% (95% CI 13, 50%) against A/H3N2, from 57% (95% CI 19, 77%) to 65% (31, 83%), against A/H1N1pdm09, and from 50% (95% CI 29, 65%) to 55% (37, 68%) against type B. (Fig. 1). Results were similar in a sensitivity analysis that excluded children < 9 years old who were partially vaccinated. VE in children was also similar across BMI categories in a sensitivity analysis that excluded LAIV recipients. Interaction terms for modification of VE by BMI category were not statistically significant (p > 0. 10) for adults or children.Fig. 1 Adjusted vaccine effectiveness against medically attended influenza A/H3N2, A/H1N1pdm09, and B by BMI category in adults and children/adolescents in the US Flu VE Network, 2011–12 through 2017–18. BMI body mass index, OR odds ratio, CI confidence interval, aVE adjusted vaccine effectiveness. *BMI categories: Adults: Normal (18.5 to < 25 kg/m2), Overweight (25 to < 30 kg/m2), Obesity (≥ 30 kg/m2); Children/adolescents: Normal (BMI percent 5 to < 85), Overweight (BMI percent 85 to < 95), Obesity (BMI percent ≥ 95). †Adjusted vaccine effectiveness—calculated as 100*(1—adjusted odds ratio). Adjusted odds ratio of vaccination status—Adjusted for site, season, age (as spline in adults; as category (2– < 9 years, 9–17 years) in children), BMI, and interaction of BMI and vaccination status.

When the 2014–15 season was excluded for A/H3N2, there was evidence that BMI category modified VE among adults (interaction p = 0.06). Compared to the main analysis, among both adults and children, A/H3N2 VE estimates increased for all BMI categories, and the trend was the same with the highest VE among adults in the overweight category, and among children in the normal category. (Supplemental Table 1, 2). Among adults, there was evidence that BMI category may modify VE against A/H3N2 when class 3 obesity is categorized separately from obesity (interaction p = 0.09), but the VE point estimates do not indicate a consistent trend of increased risk for higher BMI. Across all flu types/subtypes, the VE trends observed for distinct obesity and class 3 obesity categories had wide confidence intervals and were generally similar to the results presented in the main findings (Supplemental Table 1). VE estimates across all types/subtypes decreased when restricting the adult population to ≥ 65 years of age. None of the estimates for A/H3N2 remained statistically significant, but VE among older adults with BMI in the overweight and obesity categories were significant for A/H1N1pdm09 and B (Supplemental Table 1).

Among vaccinated adults, the adjusted odds of laboratory-confirmed influenza for all types/subtypes were significantly lower in participants with obesity vs normal weight (Table 5). Significantly lower odds of influenza among participants with obesity remained when excluding participants with plausible self-reported vaccination. Among vaccinated children, odds of infection with A/H3N2 were significantly lower among children with obesity compared to children with normal weight, but odds of infection with A/H1N1pdm09 or type B did not differ by BMI category (Table 5). The significantly lower odds of infection with A/H3N2 remained among children with obesity when excluding partially vaccinated children < 9 years of age and LAIV recipients. Table 5 Association between obesity and laboratory confirmed influenza illness in vaccine recipients, 2011–12 through 2017–18.

	A/H3N2 aOR* (95% CI)	A/H1N1pdm09 aOR* (95% CI)	B aOR* (95% CI)	
Adult BMI category†	n = 10061	n = 5646	n = 9119	
 Normal	Ref	Ref	Ref	
 Overweight	0.88 (0.77, 1.01)	0.77 (0.59, 1.00)	0.82 (0.67, 1.02)	
 Obesity	0.83 (0.73, 0.94)	0.62 (0.49, 0.79)	0.74 (0.61, 0.90)	
Children/adolescent BMI category‡	n = 3750	n = 1462	n = 3000	
 Normal	Ref	Ref	Ref	
 Overweight	0.81 (0.64, 1.03)	0.73 (0.39, 1.39)	1.0 (0.73, 1.43)	
 Obesity	0.70 (0.55, 0.88)	0.78 (0.42, 1.43)	0.75 (0.54, 1.05)	
BMI body mass index, aOR adjusted odds ratio, CI confidence interval, Ref Reference category.

*From logistic regression models adjusted for season, site, time from vaccination to illness onset (< 90 days, ≥ 90 days) and age (spline for adults; categories 2 to < 9 years, 9–17 years for children/adolescents).

†Adult BMI categories: Normal (18.5 to < 25 kg/m2), Overweight (25 to < 30 kg/m2), Obesity (≥ 30 kg/m2).

‡Children/adolescent BMI categories: Normal (BMI percent 5 to < 85), Overweight (BMI percent 85 to < 95), Obesity (BMI percent ≥ 95).

Discussion

In this analysis over multiple seasons using consistent methods from a test-negative design study of influenza VE, participants with BMI categorized as overweight or obesity at the time of illness had similar VE against medically attended influenza compared to individuals with normal weight BMI. Findings were similar in adults and children, and across all three influenza types/subtypes (A/H3N2, A/H1N1pdm09, and B). With high prevalence of obesity in the US population, even a modest reduction in VE due to obesity could have a substantial public health impact. The results from this analysis provide evidence that influenza vaccination remains effective at preventing medically attended influenza illness across a range of BMI.

Obesity is often accompanied by metabolic syndrome and other comorbidities, and these conditions may contribute to immune dysregulation and increased severity of respiratory infections31. During the 2009 influenza A/H1N1pdm09 pandemic and the COVID-19 pandemic, obesity was associated with more severe illness 32,33. The mechanism is not well-understood, but increased production of inflammatory cytokines in the lungs may be important during acute infection34. Obesity can also influence the antibody response to vaccine antigens. Impaired vaccine response in individuals with obesity was first reported in 1985 with hepatitis B vaccination of health care workers35. Few studies have assessed influenza vaccine immunogenicity and obesity, and results have been inconsistent. During the 2009–10 season, the HI response to each of the vaccine antigens was similar in a convenience sample of individuals with obesity and normal weight15. However, individuals with obesity were more likely to have a fourfold reduction in HI titer by 12 months, suggesting more rapid waning. CD8 + T cell activation was also impaired in the participants with obesity. A more recent prospective cohort study in children and adolescents in 2019–20 found that pre- and post-vaccination geometric mean HI titers were similar in participants with obesity and normal weight36.

In this study we did not assess vaccine immune response, but we observed reduced odds for laboratory-confirmed breakthrough influenza among vaccinated adults with obesity vs. those with normal weight. In vaccinated children, we observed a similar association for A/H3N2 but not for A/H1N1pdm09 or type B, which also remained with the exclusion of partially vaccinated children. The reduced odds of medically attended breakthrough influenza infection in adult vaccine recipients with obesity vs normal weight were statistically significant and ranged from 0.62 (for A/H1N1pdm09) to 0.83 (for A/H3N2). In contrast, other studies have reported elevated risk of influenza (or A/H1N1pdm09) in adults with obesity vs normal weight8,37. Given these previous findings and the accumulating evidence for obesity-related immune dysregulation, our finding was unexpected. This may be the result of residual confounding due to differences in health care seeking behaviors or differential risk of infection between individuals with obesity and normal weight. Individuals with obesity may have additional underlying medical conditions such as chronic respiratory conditions that we were unable to measure in this analysis. Higher body mass index has been associated with asthma and chronic cough38,39. Despite requiring acute cough of less than 7 days duration for enrollment, individuals with obesity may have enrolled more frequently with a cough without an infectious cause. Additionally, pre-existing respiratory conditions may increase the severity of influenza virus infection causing patients with obesity to bypass the outpatient settings from which we enrolled to seek higher levels of care.

Strengths of this study include enrollment based on symptoms rather than infection status in multiple states over seven seasons, use of the test-negative design to minimize confounding due to health care seeking behavior, and separate analyses by influenza type/subtype in adults and children/adolescents. Two different sensitivity analyses yielded results that were consistent with the primary analysis. This study also has some limitations. We were unable to assess VE against influenza emergency department visits or hospitalization and other severe outcomes. Misclassification of BMI category may have occurred because height and weight were not measured during study enrollment. Instead, BMI categories were determined from height and weight variables in EMRs. Misclassification of vaccination status is possible since we included plausible self-report without documentation of vaccine receipt in EMR.

In conclusion, this large multi-season study provides evidence that influenza vaccination reduces influenza illness and outpatient healthcare visits across a spectrum of BMI. Further research to assess the association between influenza vaccine effectiveness and obesity in the hospital setting may be beneficial since influenza related illness may be more severe in people with obesity. Our findings from the outpatient setting reinforce current recommendations for universal influenza vaccination in all adults and all children greater than 6 months of age, to protect against influenza and its complications.

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-72081-z.

Acknowledgements

The authors would like to acknowledge the following individuals for their contributions to this work: Deanna Cole, Lynn Ivacic, Sarah Kopitzke, Jennifer Meece, Madalyn Palmquist, Carla Rottscheit, Jackie Salzwedel, Sandra Strey, Maria Sundaram, Michael Smith, Chandni Raiyani, Lydia Clipper, Kempapura Murthy, Wencong Chen, Michael Reis, Teresa Ponder, Todd Crumbaker, Iosefo Iosefo, Patricia Sleeth, Virginia Gandy, Kelsey Bounds, Mary Kylberg, Arundhati Rao, Robert Fader, Kimberley Walker, Marcus Volz, Jeremy Ray, Deborah Price, Jennifer Thomas, Hania Wehbe-Janek, Madhava Beeram, John Boyd, Jamie Walkowiak, Robert Probe, Glen Couchman, Shahin Motakef and Alejandro Arroliga, Alan Aspinall, GK Balasubramani, Todd Bear, Rina Chabra, Edward Garofolo, Robert Hickey, Richard Hoffmaster, Philip Iozzi, Monika Johnson, Christopher Olbrich, Dina Perry, Jonathan Raviotta, Evelyn Reis, Brett Rosenblum, Theresa M. Sax, Michael Susick, Joe Suyama, Rachel Taber, Leonard Urbanski, Sara Walters, Alexandra Weissman, John V. Williams, Richard K. Zimmerman.

Author contributions

JPK, HQN, and EAB designed the study. JPK, HQN, ELK, CHP, MG, ETM, KMG, MPN, and EAB supervised data collection at their respective sites. JRC and BF compiled the data and provided critical feedback to shape the analysis. JPK performed the analyses and drafted the manuscript. All authors contributed to the interpretation of the data and provided critical feedback on the manuscript.

Funding

This work was supported by the US Centers for Disease Control and Prevention (CDC) (Grant numbers: 1U01IP000471 and 1U01IP001038) and CDC Grant Number IP000467 and the National Institutes of Health (NIH) grant number 1UL1 TR001857 (Pittsburgh).

Data availability

The datasets generated during and/or analysed during the current study are not publicly available because they contain coded, personally identifiable information, but may be made available from the corresponding author on reasonable request.

Competing interests

EAB and HQN receive research support from Seqirus. MPN receives research support from Sanofi. MJG received research support from MedImmune during some of the analyzed seasons and was the Texas Pediatric Society, Texas Chapter of American Academy of Pediatrics, Co-Chair, Infectious Diseases and Immunization Committee (Sep 2016–Aug 2022). ETM receives research support from Merck. JPK, ELK, CHP, KMG, JRC, and BF report no competing interests.

Ethics approval

The institutional review boards at the Centers for Disease Control and Prevention and all participating sites (Marshfield Clinic Health System IRB, Group Health Cooperative Human Subjects Review Committee/Kaiser Permanente-Washington Region IRB, Baylor Scott & White Research Institute IRB, University of Michigan IRBMED, and University of Pittsburgh Human Research Protection Office) approved the study.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. World Health Organization. Obesity and overweight, <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight> (2021).
2. Hales, C. M., Carroll, M. D., Fryar, C. D. & Ogden, C. L. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data brief, no 288. Hyattsville, MD: National Center for Health Statistics. 2017.
3. Centers for Disease Control and Prevention. Overweight & Obesity-Adult Obesity Facts, <https://www.cdc.gov/obesity/data/adult.html> (2022).
4. Coleman BL Fadel SA Fitzpatrick T Thomas SM Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: Systematic literature review and meta-analysis Influ. Other Respir. Virus. 2018 12 22 29 10.1111/irv.12504
Coleman, B. L., Fadel, S. A., Fitzpatrick, T. & Thomas, S. M. Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: Systematic literature review and meta-analysis. Influ. Other Respir. Virus. 12, 22–29. 10.1111/irv.12504 (2018).10.1111/irv.12504
5. Vitoratou DI Milas GP Korovessi P Kostaridou S Koletsi P Obesity as a risk factor for severe influenza infection in children and adolescents: A systematic review and meta-analysis Eur. J. Pediatr. 2023 182 363 374 10.1007/s00431-022-04689-0 36369400
Vitoratou, D. I., Milas, G. P., Korovessi, P., Kostaridou, S. & Koletsi, P. Obesity as a risk factor for severe influenza infection in children and adolescents: A systematic review and meta-analysis. Eur. J. Pediatr. 182, 363–374. 10.1007/s00431-022-04689-0 (2023).36369400 10.1007/s00431-022-04689-0
6. Cocoros NM Lash TL DeMaria A Jr Klompas M Obesity as a risk factor for severe influenza-like illness Influ. Other Respir. Virus. 2014 8 25 32 10.1111/irv.12156
Cocoros, N. M., Lash, T. L., DeMaria, A. Jr. & Klompas, M. Obesity as a risk factor for severe influenza-like illness. Influ. Other Respir. Virus. 8, 25–32. 10.1111/irv.12156 (2014).10.1111/irv.12156
7. Moser JS Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses Influ. Other Respir. Virus. 2018 10.1111/irv.12618
Moser, J. S. et al. Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses. Influ. Other Respir. Virus.10.1111/irv.12618 (2018).10.1111/irv.12618
8. Karki S Association between body mass index and laboratory-confirmed influenza in middle aged and older adults: A prospective cohort study Int. J. Obes. 2018 42 1480 1488 10.1038/s41366-018-0029-x
Karki, S. et al. Association between body mass index and laboratory-confirmed influenza in middle aged and older adults: A prospective cohort study. Int. J. Obes. 42, 1480–1488. 10.1038/s41366-018-0029-x (2018).10.1038/s41366-018-0029-x
9. Martin ET Epidemiology of severe influenza outcomes among adult patients with obesity in Detroit, Michigan, 2011 Influ. Other Respir. Virus. 2013 7 1004 1007 10.1111/irv.12115
Martin, E. T. et al. Epidemiology of severe influenza outcomes among adult patients with obesity in Detroit, Michigan, 2011. Influ. Other Respir. Virus. 7, 1004–1007. 10.1111/irv.12115 (2013).10.1111/irv.12115
10. Tempia S Risk factors for influenza-associated severe acute respiratory illness hospitalization in South Africa, 2012–2015 Open Forum Infect. Dis. 2017 4 ofw262 10.1093/ofid/ofw262 28480255
Tempia, S. et al. Risk factors for influenza-associated severe acute respiratory illness hospitalization in South Africa, 2012–2015. Open Forum Infect. Dis. 4, ofw262. 10.1093/ofid/ofw262 (2017).28480255 10.1093/ofid/ofw262
11. Zhou Y Adiposity and influenza-associated respiratory mortality: A cohort study Clin. Infect. Dis. 2015 60 e49 57 10.1093/cid/civ060 25645211
Zhou, Y. et al. Adiposity and influenza-associated respiratory mortality: A cohort study. Clin. Infect. Dis. 60, e49-57. 10.1093/cid/civ060 (2015).25645211 10.1093/cid/civ060
12. Callahan ST Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults Journal Infect. Dis. 2014 210 1270 1274 10.1093/infdis/jiu245 24795475
Callahan, S. T. et al. Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. Journal Infect. Dis. 210, 1270–1274. 10.1093/infdis/jiu245 (2014).24795475 10.1093/infdis/jiu245
13. Kainth MK Obesity and metabolic dysregulation in children provide protective influenza vaccine responses Viruses 2022 10.3390/v14010124 35062328
Kainth, M. K. et al. Obesity and metabolic dysregulation in children provide protective influenza vaccine responses. Viruses10.3390/v14010124 (2022).35062328 10.3390/v14010124
14. Yang WH Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial Vaccine 2013 31 4389 4397 10.1016/j.vaccine.2013.07.007 23856331
Yang, W. H. et al. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial. Vaccine 31, 4389–4397. 10.1016/j.vaccine.2013.07.007 (2013).23856331 10.1016/j.vaccine.2013.07.007
15. Sheridan PA Obesity is associated with impaired immune response to influenza vaccination in humans Int. J. Obes. 2012 36 1072 1077 10.1038/ijo.2011.208
Sheridan, P. A. et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int. J. Obes. 36, 1072–1077. 10.1038/ijo.2011.208 (2012).10.1038/ijo.2011.208
16. Talbot HK Association between obesity and vulnerability and serologic response to influenza vaccination in older adults Vaccine 2012 30 3937 3943 10.1016/j.vaccine.2012.03.071 22484350
Talbot, H. K. et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine 30, 3937–3943. 10.1016/j.vaccine.2012.03.071 (2012).22484350 10.1016/j.vaccine.2012.03.071
17. Paich HA Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus Obesity 2013 21 2377 2386 10.1002/oby.20383 23512822
Paich, H. A. et al. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity 21, 2377–2386. 10.1002/oby.20383 (2013).23512822 10.1002/oby.20383
18. Smit MA Influenza Vaccine is Protective Against Laboratory-confirmed Influenza in Obese Children Pediatr. Infect. Dis. J. 2016 35 440 445 10.1097/INF.0000000000001029 26658380
Smit, M. A. et al. Influenza Vaccine is Protective Against Laboratory-confirmed Influenza in Obese Children. Pediatr. Infect. Dis. J. 35, 440–445. 10.1097/INF.0000000000001029 (2016).26658380 10.1097/INF.0000000000001029
19. Neidich SD Increased risk of influenza among vaccinated adults who are obese Int. J. Obes. 2017 41 1324 1330 10.1038/ijo.2017.131
Neidich, S. D. et al. Increased risk of influenza among vaccinated adults who are obese. Int. J. Obes. 41, 1324–1330. 10.1038/ijo.2017.131 (2017).10.1038/ijo.2017.131
20. Centers for Disease Control and Prevention. US Flu VE Network, <https://www.cdc.gov/flu/vaccines-work/us-flu-ve-network.htm> (2023).
21. Jackson ML Influenza vaccine effectiveness in the United States during the 2015–2016 season N. Engl. J. Med. 2017 377 534 543 10.1056/NEJMoa1700153 28792867
Jackson, M. L. et al. Influenza vaccine effectiveness in the United States during the 2015–2016 season. N. Engl. J. Med. 377, 534–543. 10.1056/NEJMoa1700153 (2017).28792867 10.1056/NEJMoa1700153
22. McLean HQ Influenza vaccine effectiveness in the United States during 2012–2013: Variable protection by age and virus type J. Infect. Dis. 2015 211 1529 1540 10.1093/infdis/jiu647 25406334
McLean, H. Q. et al. Influenza vaccine effectiveness in the United States during 2012–2013: Variable protection by age and virus type. J. Infect. Dis. 211, 1529–1540. 10.1093/infdis/jiu647 (2015).25406334 10.1093/infdis/jiu647
23. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health & National Heart Lung and Blood Institute. The Practical Guide. Identification, Evaluation, and Treatment of Overweight and Obesity in Adults, <https://www.nhlbi.nih.gov/files/docs/guidelines/prctgd_c.pdf> (2000).
24. Flegal KM Kit BK Graubard BI Body mass index categories in observational studies of weight and risk of death Am. J. Epidemiol. 2014 180 288 296 10.1093/aje/kwu111 24893710
Flegal, K. M., Kit, B. K. & Graubard, B. I. Body mass index categories in observational studies of weight and risk of death. Am. J. Epidemiol. 180, 288–296. 10.1093/aje/kwu111 (2014).24893710 10.1093/aje/kwu111
25. Centers for Disease Control and Prevention & Division of Nutrition Physical Activity and Obesity. A SAS Program for the 2000 CDC Growth Charts (ages 0 to <20 years), <https://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm> (2019).
26. Centers for Disease Control and Prevention. BMI Frequently Asked Questions, <https://www.cdc.gov/bmi/faq/?CDC_AAref_Val=https://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html> (2024).
27. Cheng FW Body mass index and all-cause mortality among older adults Obesity 2016 24 2232 2239 10.1002/oby.21612 27570944
Cheng, F. W. et al. Body mass index and all-cause mortality among older adults. Obesity 24, 2232–2239. 10.1002/oby.21612 (2016).27570944 10.1002/oby.21612
28. Jackson ML Nelson JC The test-negative design for estimating influenza vaccine effectiveness Vaccine 2013 31 2165 2168 10.1016/j.vaccine.2013.02.053 23499601
Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31, 2165–2168. 10.1016/j.vaccine.2013.02.053 (2013).23499601 10.1016/j.vaccine.2013.02.053
29. Foppa IM Haber M Ferdinands JM Shay DK The case test-negative design for studies of the effectiveness of influenza vaccine Vaccine 2013 31 3104 3109 10.1016/j.vaccine.2013.04.026 23624093
Foppa, I. M., Haber, M., Ferdinands, J. M. & Shay, D. K. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 31, 3104–3109. 10.1016/j.vaccine.2013.04.026 (2013).23624093 10.1016/j.vaccine.2013.04.026
30. Centers for Disease Control and Prevention. Child Immunization Schedule Notes - Influenza Vaccination, <https://www.cdc.gov/vaccines/schedules/hcp/imz/child-schedule-notes.html#note-flu> (2023).
31. Tagliabue C Principi N Giavoli C Esposito S Obesity: Impact of infections and response to vaccines Eur. J. Clin. Microbiol. Infect. Dis. 2016 35 325 331 10.1007/s10096-015-2558-8 26718941
Tagliabue, C., Principi, N., Giavoli, C. & Esposito, S. Obesity: Impact of infections and response to vaccines. Eur. J. Clin. Microbiol. Infect. Dis. 35, 325–331. 10.1007/s10096-015-2558-8 (2016).26718941 10.1007/s10096-015-2558-8
32. Sun Y Weight and prognosis for influenza A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: A systematic review of observational studies with meta-analysis Infect. Dis. (Lond. Engl.) 2016 48 813 822 10.1080/23744235.2016.1201721
Sun, Y. et al. Weight and prognosis for influenza A(H1N1)pdm09 infection during the pandemic period between 2009 and 2011: A systematic review of observational studies with meta-analysis. Infect. Dis. (Lond. Engl.) 48, 813–822. 10.1080/23744235.2016.1201721 (2016).10.1080/23744235.2016.1201721
33. Popkin BM Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships Obes. Rev. 2020 21 e13128 10.1111/obr.13128 32845580
Popkin, B. M. et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes. Rev. 21, e13128. 10.1111/obr.13128 (2020).32845580 10.1111/obr.13128
34. Chandrasekaran R Obesity exacerbates influenza-induced respiratory disease via the arachidonic acid-p38 MAPK pathway Front. Pharmacol. 2023 14 1248873 10.3389/fphar.2023.1248873 37680710
Chandrasekaran, R. et al. Obesity exacerbates influenza-induced respiratory disease via the arachidonic acid-p38 MAPK pathway. Front. Pharmacol. 14, 1248873. 10.3389/fphar.2023.1248873 (2023).37680710 10.3389/fphar.2023.1248873
35. Weber DJ Rutala WA Samsa GP Santimaw JE Lemon SM Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine JAMA 1985 254 3187 3189 10.1001/jama.1985.03360220053027 2933532
Weber, D. J., Rutala, W. A., Samsa, G. P., Santimaw, J. E. & Lemon, S. M. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 254, 3187–3189 (1985).2933532 10.1001/jama.1985.03360220053027
36. Clarke M A prospective study investigating the impact of obesity on the immune response to the quadrivalent influenza vaccine in children and adolescents Vaccines 2022 10.3390/vaccines10050699 35632458
Clarke, M. et al. A prospective study investigating the impact of obesity on the immune response to the quadrivalent influenza vaccine in children and adolescents. Vaccines10.3390/vaccines10050699 (2022).35632458 10.3390/vaccines10050699
37. Maier HE Obesity is associated with increased susceptibility to influenza A (H1N1pdm) but Not H3N2 Infection Clin. Infect. Dis. 2021 73 e4345 e4352 10.1093/cid/ciaa928 32642771
Maier, H. E. et al. Obesity is associated with increased susceptibility to influenza A (H1N1pdm) but Not H3N2 Infection. Clin. Infect. Dis. 73, e4345–e4352. 10.1093/cid/ciaa928 (2021).32642771 10.1093/cid/ciaa928
38. Beuther DA Sutherland ER Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies Am. J. Respir. Crit. Care Med. 2007 175 661 666 10.1164/rccm.200611-1717OC 17234901
Beuther, D. A. & Sutherland, E. R. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am. J. Respir. Crit. Care Med. 175, 661–666. 10.1164/rccm.200611-1717OC (2007).17234901 10.1164/rccm.200611-1717OC
39. Morales-Estrella JL Ciftci FD Trick WE Hinami K Physical symptoms screening for cardiopulmonary complications of obesity using audio computer-assisted self-interviews Qual. Life. Res. 2017 26 2085 2092 10.1007/s11136-017-1549-x 28315177
Morales-Estrella, J. L., Ciftci, F. D., Trick, W. E. & Hinami, K. Physical symptoms screening for cardiopulmonary complications of obesity using audio computer-assisted self-interviews. Qual. Life. Res. 26, 2085–2092. 10.1007/s11136-017-1549-x (2017).28315177 10.1007/s11136-017-1549-x
